Valneva SE (NASDAQ:VALN - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $6.41, but opened at $6.22. Valneva shares last traded at $6.23, with a volume of 2,395 shares.
Analyst Upgrades and Downgrades
VALN has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th. Guggenheim cut their price objective on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th.
Get Our Latest Stock Report on Valneva
Valneva Stock Performance
The stock has a market cap of $514.28 million, a price-to-earnings ratio of -47.30 and a beta of 1.81. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company's fifty day simple moving average is $6.50 and its two-hundred day simple moving average is $5.86.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.27. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The business had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. On average, analysts forecast that Valneva SE will post 0.13 earnings per share for the current year.
Institutional Trading of Valneva
Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its stake in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after acquiring an additional 30,859 shares during the period. ABC Arbitrage SA purchased a new position in Valneva in the 4th quarter valued at approximately $84,000. Finally, GAMMA Investing LLC bought a new stake in Valneva during the 1st quarter valued at $94,000. Hedge funds and other institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Recommended Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
